BioConsortia, Inc.
PrivateLast Round
Early Funding
Oct 9, 2026
Est. Valuation
$136M
Total Funding Raised
$64M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
BioConsortia, Inc. is an agricultural biotechnology company that develops microbial products to protect plants, enhance fertility, and increase crop yields.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
BioConsortia, Inc. Comparables
Compare BioConsortia, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| NewLeaf Symbiotics | 85% | |
| Azotic Technologies Limited | 83% | |
| Jord BioScience | 83% |
BioConsortia, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | Oct 9, 2026 | ||||
| VC Round | Aug 1, 2025 | ||||
| VC Round | Apr 1, 2024 | ||||
| VC Round | Apr 19, 2023 | ||||
| Series D | Mar 13, 2018 | ||||
Series C | Oct 27, 2016 |
BioConsortia, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Square 1 Bank | Debt |
| Khosla Ventures | Series B, Series D, Series C, Seed |
| Otter Capital | Series B, Series C, VC Round, Series D, Early Funding |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 9, 2026
$15M round led by Otter Capital.
- Jul 28, 2026
Monthly visitors grew 47% MoM, reaching 1.4K.
Recent news
Latest coverage and updates
- receives_financingOct 12, 2026
On Aug 4th '25, BioConsortia Inc receives $15M in funding from its long-standing internal investors in California.
- hiresSep 18, 2026
BioConsortia Inc appoints Matthew Mouw as Vice President of Business Development in Sep '26, bringing more than three decades of agricultural science, technology and commercial leadership to the role.
- hiresSep 18, 2026
BioConsortia Inc appoints Matthew Mouw as Vice President of Business Development on Sep 18th '26, as it expands global partnerships across biostimulants, biofertilizers and biocontrol products.
- hiresSep 18, 2026
BioConsortia Inc appoints Matthew Mouw as Vice President of Business Development in the United States on Sep 21st '26 to support its commercial growth and global partnerships.
BioConsortia, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about BioConsortia, Inc.'s valuation, stock price, and market status.
Is BioConsortia, Inc. a public or private company?
BioConsortia, Inc. is a private company.
What is the current stock price of BioConsortia, Inc.?
BioConsortia, Inc. is a private company, so its shares have no public market price. Caplight tracks BioConsortia, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is BioConsortia, Inc. worth (valuation)?
BioConsortia, Inc.'s valuation is estimated at $136.0M based on funding round data.
Can I buy BioConsortia, Inc. stock?
BioConsortia, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was BioConsortia, Inc.'s last funding round?
BioConsortia, Inc.'s most recent funding round was Early Funding on October 9, 2026.
Who are the main investors in BioConsortia, Inc.?
Key investors in BioConsortia, Inc. include Square 1 Bank, Khosla Ventures, Otter Capital.
Will BioConsortia, Inc. IPO soon?
No public IPO plans have been announced for BioConsortia, Inc..
How can I track BioConsortia, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in BioConsortia, Inc.'s shares on secondary markets.